Moderna wins FDA approval for updated 2026-2027 COVID-19 vaccines targeting JN.1-lineage XFG subvariant
Reuters2026/08/27 19:58- FDA cleared Moderna’s updated 2026-2027 COVID-19 vaccine formulas targeting the JN.1-lineage XFG subvariant via sBLA approvals.
- Spikevax label covers high-risk patients aged 6 months to 64 years, plus all adults 65 years and older.
- mNEXSPIKE label covers high-risk patients aged 12 to 64 years, plus all adults 65 years and older.
- Rollout is expected in the coming days, aligning product supply with the FDA’s monovalent JN.1-lineage XFG composition guidance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japan’s Katayama: Confirmed with Bessent that continued, coordinated action on FX is needed
NTT Docomo Ventures takes stake in single-seat EV startup KG Motors
Renowned tech investor Gavin Baker: Data centers are creating a large number of high-paying blue-collar jobs
Baker believes that the construction of data centers can boost tax revenues in small towns and create high-paying blue-collar jobs. He also points out that the low natural gas prices in the United States provide a manufacturing cost advantage. He stated, "Learning trades like electrician, plumber, or HVAC technician now can earn you astonishing incomes, which in some cases might even surpass the net present value of going to college."
StrategX Elements extends non-brokered private placement deadline to Sept. 30, 2026
Crypto prices
More
